Sargent Alex, Miller Robert H
Department of Neurosciences, Case Western Reserve University, School of Medicine.
Department of Anatomy and Regenerative Medicine, George Washington University, School of Medicine and Health Sciences.
Curr Stem Cell Rep. 2016 Jun;2(2):168-173. doi: 10.1007/s40778-016-0044-6. Epub 2016 Mar 29.
The utilization of mesenchymal stem cells (also known as mesenchymal stromal cells, or MSCs) as a cell-based therapy for diseases that have ongoing inflammatory damage has become increasingly available. Our understanding of the cell biology of MSCs is still incomplete. However, as a result of increasing numbers of pre-clinical and clinical studies, general themes are emerging. The capacity of MSCs to reduce disease burden is largely associated with their ability to modulate the activity of the host immune responses rather than to contribute directly to tissue regeneration. As a result, they have significant potential in the treatment of chronic inflammatory disease regardless of the affected tissue. For example, MSC based therapies have been developed in the context of diseases as diverse as rheumatoid arthritis and multiple sclerosis. Here we discuss some of the principles that link these conditions, and the aspects of MSC biology that contribute to their use as a therapy for chronic inflammatory conditions.
间充质干细胞(也称为间充质基质细胞,或MSCs)作为一种基于细胞的疗法用于治疗存在持续炎症损伤的疾病,已越来越普遍。我们对MSCs细胞生物学的理解仍不完整。然而,随着越来越多的临床前和临床研究的开展,一些普遍的规律正在显现。MSCs减轻疾病负担的能力很大程度上与其调节宿主免疫反应活性的能力有关,而非直接促进组织再生。因此,无论受影响的组织如何,它们在治疗慢性炎症性疾病方面都具有巨大潜力。例如,基于MSCs的疗法已在类风湿性关节炎和多发性硬化症等多种疾病的背景下得到开发。在此,我们讨论一些将这些疾病联系起来的原理,以及MSCs生物学中有助于其作为慢性炎症性疾病治疗方法的方面。